NEORMATION DISCLOSURE CITATION

reral sheets if necessary)

ATTY. DOCKET NO.

4057-32

APPLICANT

APPLN. NO.

09/257,188**RECEIVED**

GLENN et al.

GROUP

FEB 0 4 2003

February 25, 1999

1644

TECH CENTER 1600/2900

				U.S. PATENT DOCUMENTS				
*EXAMINE		DOCUMENT AUMADED	DATE	NAME	CLASS	CLIBOL ACC	FILING DA	
RINITIAL	AR	3,964,482	06/1976	Gerstel et al.	TI	JUBULASS	IF AFPROFA	IAIC
/XX	BR	4,775,361	10/1988	Jacques et al.	+	 /		
-	CR	5,003,987	04/1991	Grinwald	+	 / -		
	DR	5,133,970	07/1992	Petereit et al.	+	 /-		
	ER	5,182,109 C1	10/2001	Tamura et al.	1	 /-		
1	FR	5,250,023	10/1993	Lee et al.	1	 		
	GR	5,279,544	01/1994	Gross et al.		1-1-		
	HR	5,688,523	11/1997	Garbe et al.	1	† <i>/-</i>		
	IR	5,879,326	03/1999	Godshall et al.	 	 		
	JR	5,993,849	11/1999	Assmus et al.		1/		
	KR	5,993,852	11/1999	Foldvari et al.	-	11/		
	LR	6,019,982	02/2000	Clements et al.		1 X		
	MR	6,022,316	02/2000	Eppstein et al.		1/1		
	NR	6,033,673	03/2000	Clements		/		
	OR	6,033,684	03/2000	Norcia	/			
	PR	6,063,399	05/2000	Assmus et al.	1			
	QR	6,090,790	07/2000	Eriksson				
	RR	6,142,939	11/2000	Eppstein et al.				
	\$R	6,149,919	11/2000	Domenighini et al.	 			
	TR	6,165,458	12/2000	Foldvari et al.		1		
	UR	6,165,500	12/2000	Cevc	1/	\		
	VR	6,190,367	02/2001	Hall	1/			
1	WR	6,190,689	02/2001	Hoffmann et al.	1			
13397	XR	6,207,184	03/2001	lkeda et al.				
			FC	PREIGN PATENT DOCUMENTS				
							TRANSLATI	ON
		DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YE	ES
	YR							
	ZR							
	AAR				1			
	BBR							
	CCR		ļ		 / 	 \ \ 		

|CCR|

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	DDR		
	EER		
	FFR		
	GGR		
	HHR		
	IIR		
*Examiner		tabet	11/11/03

*Examiner

INFORMATION DISCLOSURE ATTY, DOCKET NO. APPLN. NO. RECEIVED CITATION 09/257,188 4057-32 APPLICANT FEB 0 4 2003 GLENN et al. (Undersal sheets if necessary) GROUP FILING DATE **TECH CENTER 1600/2900** 1644 February 25, 1999 **U.S. PATENT DOCUMENTS** FILING DATE CLASS SUBCLASS IF APPROPRIATE DOCUMENT NUMBER DATE NAME AR 07/2001 Yuzhakov et al. 6,256,533 Roser et al. BR 6,290,991 09/2001 CR 6,312,612 11/2001 Sherman et al. DR 6,331,266 12/2001 Powell et al. ER 6,331,310 12/2001 Roser et al. FR 01/2002 6,334,856 Allen et al. GR 6,348,212 02/2002 Hymes et al. HR 6,348,450 02/2002 Tang et al. IR 6,365,178 04/2002 Venkateshwaran et al. JR 6,379,324 04/2002 Gartstein et al. KR 6.406.705 06/2002 Davis et al. LR 6,413,523 07/2002 Clements MR 6,440,096 08/2002 Lastovich et al. NR 6,451,240 09/2002 Sherman et al. OR 6,454,755 09/2002 Godshall PR 6,471,903 10/2002 Sherman et al. FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO QR WO 95/17211 06/1995 WIPO RR WIPO WO 96/06627 03/1996 SR WO 96/19976 04/1996 **WIPO** TR WO 97/04832 02/1997 WIPO UR WO 97/07734 03/1997 WIPO **VR** WO 98/00193 01/1998 **WIPO** $\overline{\mathsf{WR}}$ WO 98/29134 07/1998 WIPO XR WO 99/13915 03/1999 WIPO YR WO 99/26662 **WIPO** 06/1999 ZR WIPO WO 99/61078 12/1999 OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) **AAR** BBR CCR DDR EER FFR GGR HHR IIR JJR KKR LLR *Examiner 11/11/18

Examiner

APPLN, NO. ATTY. DOCKET NO. INFORMATION DISCLOSURE **CITATION** 4057-32 09/257,188 RECEIVED APPLICANT GLENN et al. FEB 0 4 2003 GROUP se several sheets if necessary) JAN 3 1 2003 1644 February 25, 1999 TECH CENTER 1800/201 U.S. PATENT DOCUMENTS TE TONDE FILING DATE EXAMINER CLASS SUBCLASS IF APPROPRIATE DOCUMENT NUMBER DATE NAME INITIAL FOREIGN PATENT DOCUMENTS TRANSLATION YES **DOCUMENT** DATE COUNTRY CLASS SUBCLASS NO AR WO 99/47164 09/1999 WIPO BR WO 99/47165 09/1999 **WIPO** WIPO CR WO 99/47167 09/1999 WIPO DR WO 00/33812 06/2000 **WIPO** FR WO 00/74714 12/2000 WO 00/74763 12/2000 WIPO GR WIPO HR WO 00/74763 A3 12/2000 IR WO 00/74766 12/2000 WIPO WIPO 05/2001 JR WO 01/34185 KR WO 01/90758 11/2001 WIPO LR WO 02/02179 01/2002 WIPO MR WO 02/05889 01/2002 WIPO WO 02/07813 WIPO NR 01/2002 OR WO 02/64162 08/2002 **WIPO** PR WO 02/64193 08/2002 WIPO QR WO 02/74244 09/2002 **WIPO** OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) BECKER "Dengue fever virus and Japanese encephalitis virus synthetic peptides, with motifs to fit HLA class haplotypes prevalent in human populations in endemic regions, can be used for application to skin Langerhans cells to prime antiviral CD8 cytotoxic T cells (CTLs) - A novel approach to the protection of humans" Virus Genes 9 (1994) 33-45 SR BECKER "An analysis of the role of skin Langerhans cells (LC) in the cytoplasmic processing of HIV-1 peptides after "Peplotion" transepidermal transfer and HLA class I presentation to CD8 CTLs - An approach to immunization of humans" Virus Genes 9 (1994)133-147 CASTLE "Clinical relevance of age-related immune dysfunction" Clin Infect Dis 31 (2000) 578-585 CHEN "Adjuvation of epidermal powder immunization" Vaccine 19 (2001) 2908-2917 WR CHEN "Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization" J Virol 75 (2001) 7956-7965 EL-GHORR "Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice" FEMS Immunol Med Micro 29 (2000) 255-261 GLUECK "Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine Escherichia coli heat-labile toxin as a mucosal adjuvant" J Infect Dis 181 (2000) 1129-1132 GOCKEL "Transcutaneous immunization induces mucosal and systemic immunity: A potent method for targeting immunity to the female reproductive tract" Mol Immunol 37 (2000) 537-544

~ . .

INF	INFORMATION DISCLOSURE CITATION		ATTY. DOCKET NO.			A	09/257,188 FEB 0					
			4057	4057-32			0	9/257,188	3	EB 0 4 2003		
			APPLIC		-		<u></u>		FEB	042	000	
TPE			GLE	NN et al.					TENLA	• • (ииз	
0,,,	Korke	everal sheets if necessary)	FILING				G	ROUP	JEUH C ENT	FR 100		
JAN 3 1 20	3 E		Febr	uary 25, 199	99		1	644	TECH CENT	-11 100	U/2900	
b	E)			U.S. PATENT	r DOCU	MEN	ITS					
CEXALLY		DOCUMENT NUMBER	DATE		NAM	F		CLASS	ŞUBCLASS		G DATE	
The same of the	AR		DAIL		147.0			<u> </u>	T	<u> </u>	<u> </u>	
	BR											
	CR											
	DR											
			FC	REIGN PATE	NT DO	CUM	ENTS					
	_										SLATION	
		DOCUMENT	DATE		COUNT	TRY _		CLASS	SUBCLASS	YES	NO	
	ER											
	FR											
		OTHER DOCL	JMENTS (including Au	thor, Tit	tle, C	Date, Pertii	nent pages.	etc.)			
TY	GR	HAGIWAR "Effectiven						labile enterd	toxin (LT H4	4A) as a	an	
1)4		adjuvant for nasal influ										
//	HR	HAGIWARA "Effects of										
	IR	B subunits supplemen HIOE "Comparison of										
1	1111	(1996) 412-418	aujuvann	onnulations of	Cylolox	ic i	cen maacm	on using syr	mienc pepuc	ies vac	cine 14	
	JR	· /								e" Acta		
		Derm Venereol (Stockh) 77 (1997) 365-369										
	KR	KUMAMOTO "Induction		r-specific prote	ective in	ımur	nity by <i>in si</i>	tu Langerha	ns cell vacci	ne" Nati	ire	
		Biotech 20 (2002) 64-6			 .	.						
	LH	LIU "Topical applicatio				kıne-	expression	ı plasmids ir	iduces strong	g antige	n-	
	MR	specific immune respo				/D10	2G\1 onha	nces protoc	tivo humoral	and col	lular	
	IVIT	IR LU "Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellulimmune responses to orally administered inactivated influenza vaccine" Vaccine 20 (2002) 1019-1029										
	NR McCLUSKIE "Route and method of delivery of DNA vaccine influence immune responses in mice and r											
		human primates" Mol I	Med 5 (19	99) 287-300					•		_	
		OCKENHOUSE "Sequ										
		erythrocytes identified										
		PODDA "The adjuvant vaccine" Vaccine 19 (2			ith nove	adj	uvants: Ex	perience wit	h the MF59-	adjuvate	∌ d	
					ion via c	orne	um harrier	-disrupted n	nurine skin fo	or evner	imental	
	GII	TAKIGAWA "Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis" Ann NY Acad Sci 941 (2001) 139-146										
	RR	"Tuberculin, Purified P						Reference, 3	pages (200	1)		
1501	SR	WATABE "Protection a	against inf								∍"	
100		Vaccine 19 (2001) 443	34-4444									
	TR		_ _	·								
	UR											
	VR									-		
	WR XR										<u> </u>	
	ΔH											
*Examine	r	114				1, . 1	**	Γ				
		Cuto			LL	LL	(D)					